scholarly journals Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

2019 ◽  
Vol 25 (1) ◽  
Author(s):  
Aditya Bardia ◽  
Mrinal Gounder ◽  
Jordi Rodon ◽  
Filip Janku ◽  
Martijn P. Lolkema ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Mek Inhibitor ◽  
Advanced Solid Tumors ◽  
Phosphatidylinositol 3 Kinase ◽  
Phase Ib ◽  
Phosphatidylinositol 3

scholarly journals A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (15) ◽  
pp. 4173-4182 ◽  
Author(s):  
David S. Hong ◽  
Daniel W. Bowles ◽  
Gerald S. Falchook ◽  
Wells A. Messersmith ◽  
Goldy C. George ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Phosphatidylinositol 3 Kinase ◽  
Multicenter Phase ◽  
Phosphatidylinositol 3

scholarly journals A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

2015 ◽  
Vol 26 (1) ◽  
pp. 58-64 ◽  
Author(s):  
A.W. Tolcher ◽  
J.C. Bendell ◽  
K.P. Papadopoulos ◽  
H.A. Burris ◽  
A. Patnaik ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Mek Inhibitor ◽  
Advanced Solid Tumors ◽  
Phase Ib
Sign in / Sign up

Export Citation Format

Share Document